CDK4/6 inhibition reduced abundance of MDSCs and TANs in tumor tissue, and the combined CDK4/6 inhibitors and PD-1 blockade therapy may impact dendritic cell infiltration and function in the process of antigen processing and presentation (Supplementary Fig. 19B, C). This evidence concerns the gene PDCD1 and neoplasm.